Stella Pharma Corporation

Total Valuation

Stella Pharma Corporation carries a market capitalization of 11.20B, placing it among publicly traded companies globally. Its enterprise value stands at 13.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Stella Pharma Corporation currently has 34.03M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 146.08, and the price-to-book ratio stands at 6.51.

Enterprise Valuation

Financial Position

Stella Pharma Corporation maintains a current ratio of 22.82, meaning it holds 22.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.71, indicating elevated leverage, while an interest coverage ratio of -448.75 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Stella Pharma Corporation's stock has declined approximately -19.22078% over the past 52 weeks. The 50-day moving average sits at 392.88, while the 200-day moving average is 385.13.

Income Statement

Over the trailing twelve months, Stella Pharma Corporation generated 115.50M in revenue and converted that into -457.89M in net income, yielding earnings per share of -14.49. EBITDA reached -459.07M, while operating income came in at -459.07M.

Balance Sheet

Stella Pharma Corporation holds 3.75B in cash and equivalents against 853.30M in total debt, resulting in a net debt position of -2.70B. Total book value stands at 2.59B, with working capital of 4.79B providing operational flexibility.

Margins

Stella Pharma Corporation operates with a gross margin of 81.58, reflecting its pricing power and cost economics. The operating margin of -397.47 and net profit margin of -396.46 provide insight into operational efficiency.

Scores

Stella Pharma Corporation posts an Altman Z-Score of 5.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.